Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin
Hartmut Derendorf, Jean-Marc Rolain
International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106007
A recent report identified significant reductions or disappearance of viral load in COVID-19 patients given a combination of hydroxychloroquine and azithromycin. The present communication discusses some common pharmacokinetic properties of these two drugs that may be linked to a potential underlying mechanism of action for these antiviral effects. The physicochemical properties of both hydroxychloroquine and azithromycin are consistent with particularly high affinity for the intracellular lysosomal space, which has been implicated as a target site for antiviral activity. The properties of both drugs predict dramatic accumulation in lysosomes, with calculated lysosomal drug concentrations that exceed cytosolic and extracellular concentrations by more than 50 0 0 0-fold. These predictions are consistent with previously reported experimentally measured cellular and extracellular concentrations of azithromycin. This is also reflected in the very large volumes of distribution of these drugs, which are among the highest of all drugs currently in use. The combination of hydroxychloroquine and azithromycin produces very high local concentrations in lysosomes. The clinical significance of this observation is unclear; however, the magnitude of this mechanism of drug accumulation via ion-trapping in lysosomes could be an important factor for the pharmacodynamic effects of this drug combination.
Declarations
References
Barbour, Scaglione, Derendorf, Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices, Int J Antimicrob Agents
Carlier, Garcia-Luque, Montenez, Tulkens, Piret, Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture, Int J Tissue React
Colson, Rolain, Lagier, Brouqui, Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int J Antimicrob Agents
Colson, Rolain, Raoult, Chloroquine for the 2019 novel coronavirus SARS-CoV-2, Int J Antimicrob Agents
Cook, Randinitis, Bramson, Wesche, Lack of a pharmacokinetic interaction between azithromycin and chloroquine, Am J Trop Med Hyg
Cutler, Introduction: lysosome-related organelles, Semin Cell Dev Biol
Devaux, Rolain, Colson, Raoult, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?, Int J Antimicrob Agents
Fossa, Wisialowski, Duncan, Deng, Dunne, Azithromycin/ chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig, Am J Trop Med Hyg
Gautret, Lagier, Parola, Hoang, Meddeb et al., Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study, Travel Med Infect Dis,
doi:10.1016/j.tmaid.2020.101663Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105949Hoof, Tulkens, Gentamicin-induced lysosomal phospholipidosis in cultured rat fibroblasts. Quantitative ultrastructural and biochemical study, Lab Invest
Juurlink, Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection, CMAJ,
doi:10.1503/cmaj.200528Kakeya, Seki, Izumikawa, Kosai, Morinaga et al., Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study, PLoS One
Kazmi, Hensley, Pope, Funk, Loewen et al., Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells), Drug Metab Dispos
Lemaire, Tulkens, Van Bambeke, Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils, Antimicrob Agents Chemother
Macintyre, Cutler, The potential role of lysosomes in tissue distribution of weak bases, Biopharm Drug Dispos
Macintyre, Cutler, role of lysosomes in hepatic accumulation of chloroquine, J Pharm Sci
Min, Jang, Macrolide therapy in respiratory viral infections, Mediators Inflamm
Molina, Delaugerre, Goff, Lima, Ponscarme et al., No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection, Med Mal Infect,
doi:10.1016/j.medmal.2020.03.006Ohrt, Willingmyre, Lee, Knirsch, Mihous, Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro, Antimicrob Agents Chemother
Pfizer, Zithromax product information
Poole, Ohkuma, Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages, J Cell Biol
Rolain, Colson, Raoult, Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century, Int J Antimicrob Agents
Schroeder, Gerber, Chloroquine and hydroxychloroquine binding to melanin: Some possible consequences for pathologies, Toxicol Rep
Simmons, Bertram, Glowacka, Steffen, Chaipan et al., Different host cell proteases activate the SARS-coronavirus spike-protein for cell-cell and virus-cell fusion, Virology
Steinman, Brodie, Cohn, Membrane flow during pinocytosis. A stereologic analysis, J Cell Biol
Tett, Cutler, Day, Brown, A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers, Br J Clin Pharmacol
Thummel, Shen, Isoherranen, Smith, Design and optimization of dosage regimens: pharmacokinetic data. Goodman & Gilman's The Pharmacological Basis of Therapeutics
Tyteca, Van Der Smissen, Mettlen, Van Bambeke, Tulkens et al., Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages, Exp Cell Res
Tyteca, Van Der Smissen, Van Bambeke, Leys, Tulkens et al., Azithromycin, a lysosomotropic antibiotic, impairs fluid-phase pinocytosis in cultured fibroblasts, Eur J Cell Biol
Van Bambeke, Montenez, Piret, Tulkens, Courtoy et al., Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity, Eur J Pharmacol
Wibo, Poole, Protein degradation in cultured cells. II. The uptake of chloroquine by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B1, J Cell Biol
Yang, Huang, Ganesh, Leung, Kong et al., pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN, J Virol
Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis,
doi:10.1093/cid/ciaa237Zheng, Matzneller, Zeitlinger, Schmidt, Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects, Antimicrob Agents Chemother
